Why the study?
The optimal duration of anticoagulant therapy for venous thromboembolic complications using oral anticoagulants needed to be addressed.
What is the optimal duration of oral anticoagulant therapy for venous thromboembolic complications?
What is the optimal duration of oral anticoagulant therapy for venous thromboembolic complications?
Oral anticoagulants offer a safe option for prolonged treatment of venous thromboembolism, though duration must be individualized based on recurrence and bleeding risks.
Supports individualized OAC duration in VTE; leaves open prospective trials to refine risk thresholds.
The review is devoted to the issue of optimal duration of anticoagulant therapy for venous thromboembolic complications (VTEC) using oral anticoagulants (OAC). These drugs are characterized by higher safety in comparison with vitamin K antagonists and make it possible to increase the duration of treatment for not only spontaneous thrombosis (with high risk of recurrence), but also thrombosis provoked by minor persistent and transient risk factors of VTEC. Efficacy and safety of prolonged treatment of VTEC using OAC was analyzed. Different classifications of primary thrombotic episode depending on risk of subsequent recurrence are presented. Moreover, scales for individual assessment of risk of recurrent thrombosis after anticoagulant therapy cancellation and risk of bleeding in case of continued treatment are given. Outcomes of long-term administration of rivaroxaban for VTEC are analyzed. It was concluded that OAC are safe for prolonged management of primary thrombotic episode. However, overall duration of treatment should be determined considering individual balance of benefits and risks.
No takes yet. Share an insight, caveat, or question.
Kirill Lobastov (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on Anticoagulation in AFMore from Pirogov Russian Journal of Surgery